Drug intelligence / Profile preview

amantadine + levodopa

Development stage
Phase 4
Lead developer
Supernus Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

A combination therapy used primarily for the treatment of Parkinson's disease. This combination therapy has been studied extensively and shows improved efficacy compared to either drug alone in managing Parkinson's symptoms. Amantadine works through multiple mechanisms, including increasing dopamine release in the brain and antagonizing NMDA receptors. L-DOPA (levodopa) is considered the gold standard treatment for Parkinson's disease. When used together with amantadine, the combination has been shown to be more effective than levodopa alone in managing total functional disability, tremor, gait issues, and improving various motor functions. Clinical studies have demonstrated that the combination of levodopa and amantadine is particularly beneficial for treating dyskinesia (involuntary movements) that can occur as a side effect of long-term levodopa use. Amantadine is currently the only available medication specifically approved to treat levodopa-induced dyskinesia. The combination therapy improves grip strength, finger coordination, tracking, tandem gait, and various practical skills used in daily living such as zipping, cutting, and opening doors.

Other names
amantadine + L-DOPA
02

Targets

DRD5 (Dopamine D5 Receptor)NMDAR (Glutamate receptor ionotropic, NMDA)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on amantadine + levodopa.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on amantadine + levodopa.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call